



# GLAND PHARMA LIMITED

January 16, 2025

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex  
Bandra (East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad**

**Ref: Announcement made by the Company dated July 25, 2024**

In continuation to our intimation dated July 25, 2024; this is to inform you that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company's Dundigal Facility at Hyderabad between 22<sup>nd</sup> July, 2024 and 25<sup>th</sup> July, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Request to take the above information on record.

Yours truly,

**For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi**  
**Company Secretary & Compliance Officer**

**Regd. Office:**

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads  
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal  
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India  
Tel: +91-40-30510999 Fax: +91-40-30510800

**Corporate Office:**

Plot No. 11 & 84, TSIC Phase: IV  
Pashamylaram (V), Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India  
Tel: +91-8455-699999